文献速递疼痛医学

鞘内药物输注治疗慢性非癌性疼痛的设备取出并发症分析

Complications leading to device explant in patients with chronic non-cancer pain receiving intrathecal drug delivery.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

本研究回顾性分析了215例接受鞘内药物输注(IDD)治疗的慢性非癌性疼痛患者,平均随访80±48.8个月,设备取出率为26.1%。设备相关感染是取出的主要原因,发生于9.3%的患者和5.9%的设备手术中;因镇痛疗效丧失而取出的比例为5.6%,显著低于类似人群脊髓电刺激(SCS)的因习惯化取出的比例。无人口学或合并症因素与设备取出相关。

要点

  • IDD治疗慢性非癌性疼痛的设备取出率为26.1%,感染是首要原因。
  • 因镇痛疗效丧失取出IDD的比例为5.6%,低于类似人群SCS因习惯化取出的比例。
  • 感染导致的取出时间间隔显著短于其他并发症。

核心结论

  • 设备相关感染是慢性非癌性疼痛患者IDD取出的主要原因。
  • 因镇痛疗效丧失而取出IDD的频率低于类似人群SCS因习惯化取出的频率。

研究设计与样本

  • 回顾性研究,纳入2009年6月至2022年12月期间由疼痛医学医师植入设备的慢性非癌性疼痛患者。
  • 共215例患者,平均随访80±48.8个月,植入时平均年龄63.24±12.05岁,其中184例为PSPS2。

主要发现

  • 设备取出率为26.1%。
  • 设备相关感染发生于9.3%的患者和5.9%的设备手术中。
  • 因镇痛疗效丧失导致设备取出发生于5.6%的患者,显著低于类似人群SCS因习惯化取出的比例。
  • 与其他并发症相比,感染从植入到取出的时间间隔更短。
  • 无人口学或合并症因素与设备取出相关。

临床怎么用

  • 临床应重视IDD设备相关感染的预防与监测,感染是取出的首要原因且发生时间较早。
  • 对于慢性非癌性疼痛患者,IDD在镇痛疗效维持方面可能优于SCS,因疗效丧失取出的比例较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Intrathecal drug delivery (IDD) is often used in the management of refractory chronic non-cancer pain, particularly persistent chronic low back pain in the setting of previous lumbar spine surgery (persistent spinal pain syndrome type 2 (PSPS2)). Complications of IDD leading to device explant in patients with chronic non-cancer pain have not been well characterized. This study evaluated complications leading to device explants in a large cohort of patients with chronic non-cancer pain treated with IDD. METHODS: A retrospective study was undertaken on patients with chronic non-cancer pain who underwent device implants by Pain Medicine physicians between June 2009 and December 2022 at a large tertiary center academic practice. Data collection included demographic and comorbidity data as well as the various indications for device explant. RESULTS: Data were collected from 215 patients with chronic non-cancer pain who underwent device implant and were followed for a mean duration of 80±48.8 months. The average age at the time of implant was 63.24±12.05 years, and the majority (184 patients) suffered from PSPS2. The explant rate was 26.1%, and device-related infection was the leading cause of explants occurring in 9.3% of patients and 5.9% of device surgeries. Loss of analgesic efficacy leading to device explant occurred in 5.6% of patients, but this was significantly less than the explant rate due to habituation noted with spinal cord stimulation (SCS) in a similar patient population. compared with other complications leading to device explants, infections had a much earlier time interval from device implant to explant. No demographic or comorbidity factors correlated with device explants. CONCLUSION: Device-related infections are the leading cause for explants in IDD for chronic non-cancer pain. Explants due to loss of analgesic efficacy occurred at a lesser frequency with IDD compared with SCS explants in a similar patient population.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Hayek SM, Shahrestani S, Blank J, et al. Complications leading to device explant in patients with chronic non-cancer pain receiving intrathecal drug delivery. Reg Anesth Pain Med. 2026. PMID: 42710947. doi:10.1136/rapm-2025-107223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。